Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2012 December 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Nintedanib		
Initial application — idiopathic pulmonary fibrosis Applications only from a respiratory specialist. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate) Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist and Forced vital capacity is between 50% and 90% predicted and Nintedanib is to be discontinued at disease progression (See Note) and Nintedanib is not to be used in combination with subsidised pirfenidone and The patient has not previously received treatment with pirfenidone or Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance or Patient has previously received pirfenidone, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone)		
Renewal — idiopathic pulmonary fibrosis		
Current approval Number (if known):		
Prerequisites (tick boxes where appropriate)		
Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment and Nintedanib is not to be used in combination with subsidised pirfenidone		
and Nintedanib is not to be used in combination with subsidised pirtenidone and Nintedanib is to be discontinued at disease progression (See Note)		

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

I confirm the above details are correct and that in signing this form I understand I may be audited.